Exploiting the tumour microenvironment for the development of immunotherapies against solid tumours
Aim of the project
The generation of a new breast cancer immunotherapy targeting Syndecan-3 could lead to reduced mortality rates, improved quality of life, and decreased healthcare costs for patients, while also stimulating research and development in breast cancer prevention and treatment.
